KRAS and colorectal carcinoma: In an exciting recent case study, CTLs expanded from TILs of a CRC patient specifically recognized an HLA-C*0802-restricted KRAS peptide containing the G12D mutation; furthermore, these TILs were shown to mediate an objective tumor regression of multiple lung metastases in the patient following infusion26.